As Zantac Litigation Accelerates, MDL Data Collection Is Key
On April 1, the U.S. Food and Drug Administration initiated a market withdrawal request for ranitidine products (e.g., Zantac).[1] This request comes on the heels of two important recent developments....To view the full article, register now.
Already a subscriber? Click here to view full article